Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
KRBP Kiromic BioPharma		$1.16	$0.16 ▼ $3.32	$330K	1.66	11,347 shs	107,749 shs
SRNE Sorrento Therapeutics	$0.00 -24.6%	$0.00	$0.00 ▼ $0.02	$2.37M	0.85	121,918 shs	70,004 shs
ZVSA ZyVersa Therapeutics	$0.14 -5.7%	$0.39	$0.11 ▼ $3.37	$1.10M	0.75	3.35 million shs	40,940 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
KRBP Kiromic BioPharma	0.00%	0.00%	0.00%	0.00%	-90.37%
SRNE Sorrento Therapeutics	-24.56%	+104.76%	+230.77%	+230.77%	-57.00%
ZVSA ZyVersa Therapeutics	-5.71%	-10.23%	-41.02%	-74.33%	-96.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	0.7146 of 5 stars	0.0	2.0	0.0	4.3	0.0	0.0	0.0
ZVSA ZyVersa Therapeutics	0.6414 of 5 stars	0.0	4.0	0.0	0.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	($8.29) per share	N/A
SRNE Sorrento Therapeutics	$60.32M	0.04	N/A	N/A	N/A	∞
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	∞	N/A	N/A	-8,454.87%	-121.60%	N/A
KRBP Kiromic BioPharma	-$26.90M	-$3.50	N/A	N/A	N/A	N/A	N/A	-277.46%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	-$9.41M	N/A	0.00	N/A	N/A	N/A	-109.54%	-43.95%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
KRBP Kiromic BioPharma	N/A	0.16	0.22
SRNE Sorrento Therapeutics	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
KRBP Kiromic BioPharma	10.91%
SRNE Sorrento Therapeutics	0.02%
ZVSA ZyVersa Therapeutics	3.91%

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
KRBP Kiromic BioPharma	20.59%
SRNE Sorrento Therapeutics	2.60%
ZVSA ZyVersa Therapeutics	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	Optionable
KRBP Kiromic BioPharma	60	1.57 million	1.22 million	Not Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data
ZVSA ZyVersa Therapeutics	2	7.94 million	4.86 million	Not Optionable

KRBP, ASLN, SRNE, and ZVSA Headlines

Recent News About These Companies

ZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq Delisting

August 20 at 4:54 AM | msn.com

ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...

August 14, 2025 | bakersfield.comB

ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

August 14, 2025 | globenewswire.com

ZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product Development

August 13, 2025 | quiverquant.comQ

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

August 13, 2025 | globenewswire.com

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

July 21, 2025 | globenewswire.com

ZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading Thursday

July 16, 2025 | marketwatch.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | Morningstar

July 9, 2025 | morningstar.comM

ZyVersa’s VAR 200 approved for emergency use in rare kidney disease

July 9, 2025 | uk.investing.com

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - Nasdaq

July 9, 2025 | nasdaq.com

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

July 8, 2025 | benzinga.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | finanznachrichten.de

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis

July 8, 2025 | quiverquant.comQ

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediatorâ„¢Â VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - Nasdaq

June 27, 2025 | nasdaq.com

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...

June 26, 2025 | morningstar.comM

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...

June 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRBP, ASLN, SRNE, and ZVSA Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 08/21/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Kiromic BioPharma NASDAQ:KRBP

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Sorrento Therapeutics NASDAQ:SRNE

$0.0043 0.00 (-24.56%)

As of 08/22/2025 03:59 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

ZyVersa Therapeutics NASDAQ:ZVSA

$0.14 -0.01 (-5.71%)

As of 08/22/2025 03:17 PM Eastern

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time